Drug Profile
M 4112
Alternative Names: M4112Latest Information Update: 28 Dec 2020
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antineoplastics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Dec 2020 No recent reports of development identified for phase-I development in Solid-tumours in Unknown
- 03 Apr 2019 Safety, efficacy and pharmacokinetic data from a phase I trial in Solid tumours presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)
- 01 Nov 2017 Phase-I clinical trials in Solid tumours before November 2017 (Merck pipeline, November 2017)